More than a half-dozen billionaire money managers pared down their stakes in Nvidia during the December-ended quarter and bought shares of two high-octane artificial intelligence (AI) companies.With few exceptions over the last three decades, investors have always had a next-big-thing investment trend or innovation to look forward to. But since the advent of the internet in the mid-1990s, other next-big-thing trends have consistently come up short. The rise of artificial intelligence (AI) aims to change tha ...

Intuitive Surgical, Inc. (ISRG) is well-poised for growth in the coming quarters, courtesy of its strength in robotics. The optimism, led by the solid 2023 results and its progress on the Artificial Intelligence (AI) front, is expected to contribute further. However, procedure adoption risks and stiff competition persist.Shares of this Zacks Rank #3 (Hold) company have risen 14.6% so far this year compared with the industry’s 7.3% growth. The S&P 500 Index has gained 9.7% during the same time frame.Intuitiv ...

Lewis Chew elected to Intuitive's BoardAlan Levy, PhD and Don Kania, PhD to retire from Board SUNNYVALE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that Lewis Chew, former chief financial officer at Dolby Labs, Inc., has been elected to the Company's Board of Directors, effective April 25. "Lewis brings decades of experience across global organizations, technologies, an ...

Visitors look at a surgical robot at the booth of IntuitiveFosun at the 6th China International ... [+] Import Expo CIIE in east China's Shanghai, Nov. 7, 2023. (Photo by Jin Haoyuan/Xinhua via Getty Images)Xinhua News Agency via Getty ImagesIntuitive Surgical Intuitive Surgical (NASDAQ NASDAQ : ISRG) recently reported its Q1 results, with revenues and earnings beating the street estimates. The company reported revenue of $1.89 billion and adjusted earnings of $1.50 per share, compared to the consensus esti ...

Key PointsIntuitive Surgical is the pioneer and leading provider of robotic-assisted surgical systems.The da Vinci Surgical systems augment the capabilities of surgeons with 10X vision and smooth tremor, less fuller range of motion to perform precision robot-assisted surgeries.Intuitive Surgical grew its installed base of da Vinci systems 14% YoY to 8.887 worldwide.5 stocks we like better than Intuitive SurgicalWhile artificial intelligence (AI) and robots are in the spotlight regularly these days, there's ...

Company Performance - Intuitive Surgical reported $1 89 billion in revenue for Q1, a nearly 12% year-over-year (YOY) gain, outpacing consensus by 100 basis points [2] - Procedure volume increased by 16%, driven by a 90% increase in ion bronchoscopy procedures and a 14% increase in the installed machine base [2] - Instruments & Accessories segment led revenue growth, up 18%, while Systems revenue declined by 2% due to end-user mix [2] - Services revenue grew by 10% [2] - GAAP net income increased by 53%, GAAP earnings by 51%, and adjusted earnings by 22%, 560 basis points better than consensus [2] - Operating costs rose only 7%, contributing to a widening operating margin [2] Market Position and Growth Drivers - Intuitive Surgical is the industry leader in medtech, outperforming expectations and benefiting from the widening use of DaVinci systems and deeper market penetration [1][2] - The company is experiencing industry normalization and a global backlog of procedures, which are expected to drive continued growth [1][2] - Analysts have raised price targets, with a range of $375 to $436, reflecting potential upside of 1% to 18% [4] - The stock recently broke out to a new high and is now retesting support levels, with critical support near $358 [5] Analyst Sentiment and Institutional Activity - Analysts rate Intuitive Surgical as a "Moderate Buy," with steady consensus over the past twelve months [4] - Insider selling occurred in Q1 2024, but insiders own only 0 90% of the company, and their activity is not seen as a significant red flag given the strong results [4] - Institutions own approximately 84% of the stock, with light activity that has supported the market over the past year [4] Competitive Landscape - While Intuitive Surgical is a top performer, some analysts recommend five other stocks as better buys, though Intuitive Surgical remains a strong contender in the medtech space [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30713 Intuitive Surgical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 77-0416458 (State or Other Jurisd ...

Earnings and Revenue Performance - Intuitive Surgical reported adjusted earnings of $1 50 per share for Q1 2024, surpassing Wall Street's estimate of $1 41 per share [2] - Revenue for the quarter reached $1 89 billion, an 11% year-over-year increase, exceeding the forecast of $1 87 billion [2] - The company's instruments and accessories business saw an 18% sales growth, driven by a 16% increase in da Vinci procedure volume and a 90% surge in Ion procedure volume [2] Product and Market Developments - The da Vinci robotic platform achieved a 16% year-over-year global procedure growth [1] - The next-generation da Vinci 5 robotic system received FDA clearance in March 2024, with eight systems placed by the end of Q1 [2] - The Ion procedure, a robot-assisted biopsy, contributed significantly to the growth in procedure volumes [2] Industry Trends and Competitor Insights - Growing demand for robotics-assisted procedures aligns with Johnson & Johnson's recent remarks, indicating elevated medical technology-related procedure volumes through 2024 [3] - The medical devices industry is experiencing increased adoption of robotic solutions for minimally invasive surgeries [1][3] Stock Performance and Technical Analysis - Intuitive Surgical shares rose over 3% in after-hours trading following the earnings report [1] - The stock has been rangebound since early March 2024, with potential resistance around the $403 level, identified by a trendline linking three recent price peaks [1][3] - A golden cross buy signal was generated in late December 2023, when the 50-day moving average crossed above the 200-day moving average [3]

Intuitive Surgical, Inc. (NASDAQ:ISRG) Q1 2024 Earnings Conference Call April 18, 2024 4:30 PM ET Company Participants Brian King - Head of Investor Relations Gary Guthart - Chief Executive Officer Jamie Samath - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Rick Wise - Stifel Adam Maeder - Piper Sandler Drew Ranieri - Morgan Stanley Matt Miksic - Barclays Brandon Vazquez - William Blair Jayson Bedford - Raymond Jam ...

For the quarter ended March 2024, Intuitive Surgical, Inc. (ISRG) reported revenue of $1.89 billion, up 11.5% over the same period last year. EPS came in at $1.50, compared to $1.23 in the year-ago quarter.The reported revenue represents a surprise of +1.39% over the Zacks Consensus Estimate of $1.86 billion. With the consensus EPS estimate being $1.40, the EPS surprise was +7.14%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to det ...